Global Retinal Vein Occlusion Market Research Report - Forcast To 2023

The branch retinal artery occlusion is expected to grow at the fastest CAGR of 11.6% during the forecast period from 2017–2023.

Reference: 180334
Price: $4,450.00
Tax included

General

Geography Covered
Global
Publisher:
Market Research Future
Publication Date
2018/2/5
Pages
150
Language
  • English
Format
License

Introduction
Retinal vein occlusion is a retinal vascular disease that mainly affects the older population and causes blindness. The condition is basically of two types, namely, Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO). BRVO is the condition when the blockage occurs in the branch of the retinal vein and blood with fluid spills out into the retina. On the other hand, CRVO is the condition when the blockage occurs in the main retinal vein and blood, and fluid spills out into the retina.
It is noted that the increasing prevalence of diabetes and atherosclerosis, is the key factor driving the retinal vein occlusion market. Various other factors such as the increasing prevalence of glaucoma, lymphoma, and multiple myeloma, and change in lifestyles are also propelling the growth of the market.
The global retinal vein occlusion market is segmented by type, condition, diagnosis, treatment, end-user, and region.
The market for retinal vein occlusion, by type, is segmented into branch retinal artery occlusion and central retinal vein occlusion, in which the branch retinal artery occlusion accounted for the largest market share in 2016. The branch retinal artery occlusion is expected to grow at the fastest CAGR of 11.6% during the forecast period from 2017–2023.
The retinal vein occlusion market is further segmented, by condition. The condition segment is classified as non-ischemic and ischemic. The non-ischemic segment is projected to grow at the fastest CAGR of 11.6% during the forecast period from 2017–2023.
The retinal vein occlusion market, by diagnosis, is segmented into Optical Coherence Tomography (OCT), fundoscopic examination, fluorescein angiography, and others. The fundoscopic examination segment is projected to grow at the fastest CAGR of 11.6% during the forecast period from 2017–2023.
The retinal vein occlusion market, by treatment, is segmented into antivascular endothelial growth factor, corticosteroid drugs, laser retinal photocoagulation, and others. The corticosteroid drugs segment is projected to grow at the fastest CAGR of 11.64% during the forecast period from 2017–2023.

Further, the market is segmented by end-user, which includes hospitals and clinics, research and academics center, and others. Hospitals and clinics accounted for the largest market share in 2016.
By region, the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The European region captured the largest market globally and is expected to reach USD 15,889.59 million by 2023.
Key Players
Some of the key players in this market are Allergan Plc, Bayer, Bristol-Myers Squibb, Ellex Medical Lasers Ltd., GlaxoSmithKline plc, IRIDEX Corporation, Lumenis, Novartis, NIDEK CO., LTD., Regeneron Pharmaceuticals, F. Hoffmann-La Roche AG, Quantel Medical Inc, Topcon Medical Systems, Inc., and ZEISS.

Study objectives
• To provide insights into factors influencing and affecting the market growth
• To provide historical and forecast revenue of market segments and sub-segments with respect to countries
• To provide historical and forecast revenue of market segments based on type, condition, diagnosis, treatment, end-user, and region
• To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market
• To provide economic factors that influence the global retinal vein occlusion market
• To provide a detailed analysis of the value chain and supply chain of the global retinal vein occlusion market
Target Audience
• Pharmaceutical and Biotech Industries
• Potential Investors
• Medical Research Institutes
• Key Executive (CEO and COO) and Strategy Growth Manager
• Research Companies
Key Findings
• The global retinal vein occlusion market is expected to grow at a rate of 11.2% during the forecast period, 2017 to 2023. The increasing R&D spending, growing healthcare industry, and increased spending on technological advancements are driving the growth of the market
• The branch retinal artery occlusion segment commanded the largest market share in terms of type, in 2016, and is expected to register a CAGR of 11.6% during the forecast period, 2017–2023
• However, the high cost of treatment and side-effects associated with it may hinder the growth of the market

Regional Analysis
Americas
• North America
o U.S.
o Canada
• South America
Europe
• Western Europe
o Germany
o France
o U.K.
o Italy
o Spain
o Rest of Western Europe
• Eastern Europe
Asia Pacific
o Japan
o China
o India
o Australia
o South Korea
o Rest of Asia Pacific
Middle East & Africa
• Middle East
o United Arab Emirates
o Saudi Arabia
o Kuwait
o Qatar
o Africa

 

Table of Contents:

1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope of Study
2.3 Research Objective
2.4 Assumptions & Limitations
2.4.1 Assumptions
2.4.2 Limitations
2.5 Market Structure
3 Research Methodology
3.1.1 Primary Research Methodology
3.1.2 Secondary Research Methodology
3.1.3 Market Share Analysis
3.1.4 Market Pricing Approach
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Increasing prevalence of diabetes and atherosclerosis (Impact Weightage 40%)
4.2.2 Change in lifestyle (Impact Weightage 35%)
4.2.3 Increasing prevalence of glaucoma, lymphoma, and multiple myeloma (Impact Weightage 25%)
4.3 Restraints
4.3.1 Side effect of treatment (Impact Weightage 60%)
4.3.2 High cost of treatment (Impact Weightage 40%)
5 Market Factor Analysis
5.1 Porters Five Forces Model
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.2.1 R&D
5.2.2 Manufacturing
5.2.3 Distribution & Sales
5.2.4 Post-sales Monitoring
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
5.5 Investment Opportunity Analysis
6 Global Retinal Vein Occlusion Market, By Type
6.1 Branch Retinal Artery Occlusion
6.2 Central Retinal Vein Occlusion
7 Global Retinal Vein Occlusion Market, By Condition
7.1 Non-Ischemic
7.2 Ischemic
8 Global Retinal Vein Occlusion Market, By Diagnosis
8.1 Optical Coherence Tomography
8.2 Fundoscopic Examination
8.3 Fluorescein Angiography
9 Global Retinal Vein Occlusion Market, By Treatment
9.1 Antivascular Endothelial Growth Factor
9.1.1 Aflibercept
9.1.2 Ranibizumab
9.2 Corticosteroid Drugs
9.2.1 Triamcinolone Acetonide
9.2.2 Dexamethasone
9.3 Laser Retinal Photocoagulation
10 Global Retinal Vein Occlusion Market, By End User
10.1 Hospitals and Clinics
10.2 Research & Academics Centers
11 Global Retinal Vein Occlusion Market, By Region
11.1 Americas
11.1.1 North America
11.1.1.1 U. S.
11.1.1.2 Canada
11.1.2 South America
11.2 Europe
11.2.1 Western Europe
11.2.1.1 Germany
11.2.1.2 France
11.2.1.3 U.K
11.2.1.4 Italy
11.2.1.5 Spain
11.2.1.6 Rest of Western Europe
11.2.2 Eastern Europe
11.3 Asia Pacific
11.3.1 Japan
11.3.2 China
11.3.3 India
11.3.4 Australia
11.3.5 Republic of Korea
11.3.6 Rest of Asia Pacific
11.4 Middle East & Africa
11.4.1 Africa
12 Competitive Landscape
12.1 Introduction
12.2 Company Share Analysis
13 Company Profiles
13.1 Allergan Plc
13.1.1 Company Overview
13.1.2 Financials
13.1.3 Products
13.1.4 Strategy
13.1.5 Key Developments
13.2 Bayer
13.2.1 Company Overview
13.2.2 Financials
13.2.3 Products
13.2.4 Strategy
13.2.5 Key Developments
13.3 Bristol-Myers Squibb
13.3.1 Company Overview
13.3.2 Financials
13.3.3 Products
13.3.4 Strategy
13.3.5 Key Developments
13.4 Ellex Medical Lasers Ltd.
13.4.1 Company Overview
13.4.2 Financials
13.4.3 Products
13.4.4 Strategy
13.4.5 Key Developments

13.5 GlaxoSmithKline plc
13.5.1 Company Overview
13.5.2 Financials
13.5.3 Products
13.5.4 Strategy
13.5.5 Key Developments
13.6 IRIDEX Corporation
13.6.1 Company Overview
13.6.2 Financials
13.6.3 Products
13.6.4 Strategy
13.6.5 Key Developments
13.7 Lumenis
13.7.1 Company Overview
13.7.2 Financials
13.7.3 Products
13.7.4 Strategy
13.7.5 Key Developments
13.8 Novartis
13.8.1 Company Overview
13.8.2 Financials
13.8.3 Products
13.8.4 Strategy
13.8.5 Key Developments
13.9 NIDEK CO.,LTD.
13.9.1 Company Overview
13.9.2 Financials
13.9.3 Products
13.9.4 Strategy
13.9.5 Key Developments
13.1 Regeneron Pharmaceuticals
13.10.1 Company Overview
13.10.2 Financials
13.10.3 Products
13.10.4 Strategy
13.10.5 Key Developments
13.11 F. Hoffmann-La Roche AG
13.11.1 Company Overview
13.11.2 Financials
13.11.3 Products
13.11.4 Strategy
13.11.5 Key Developments

13.12 Quantel Medical Inc
13.12.1 Company Overview
13.12.2 Financials
13.12.3 Products
13.12.4 Strategy
13.12.5 Key Developments
13.13 Topcon Medical Systems, Inc.
13.13.1 Company Overview
13.13.2 Financials
13.13.3 Products
13.13.4 Strategy
13.13.5 Key Developments
13.14 ZEISS
13.14.1 Company Overview
13.14.2 Financials
13.14.3 Products
13.14.4 Strategy
13.14.5 Key Developments
14 MRFR Conclusion
14.1 Key Findings
14.1.1 From CEO’s View Point
14.1.2 Unmet Needs
14.2 Key companies to watch
15 Appendix
15.1 Discussion Blue Print

 

Scroll